CUL4B as predictive biomarker for cancer treatment
The current disclosure describes materials and methods for identifying subjects that would benefit from treatment with a DNA topoisomerase 1 inhibitor, based on the levels of cullin 4B gene, RNA and protein levels in the subject. The disclosure identifies CUL4B as a predictive biomarker for cancer diagnosis and the subsequent treatment with directed therapeutic agents. The current disclosure also identifies novel therapeutic agents that modulate the level of CUL4B expression, and sensitize a subject to treatment with a second therapeutic agent.
1. A method of treating cancer in a subject who has been identified as expressing an elevated level of CUL4B, comprising administering to the subject an effective amount of an agent that inhibits expression or activity of CUL4B, and a Top1-directed chemotherapeutic compound, wherein inhibition of expression of CUL4B sensitizes said cancer to the Top1-directed chemotherapeutic compound, and wherein the agent is a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6 and SEQ ID NO. 7.
2. A method of sensitizing a cancer patient to a Top1-directed chemotherapeutic compound, comprising:
obtaining a biological from a human subject;
determining that the sample has elevated expression of CUL4B;
administering to the subject an effective amount of an agent that inhibits expression or activity of CUL4B, wherein inhibition of expression of CUL4B sensitizes said cancer to the Top1-directed chemotherapeutic compound, and wherein the agent is a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6 and SEQ ID NO. 7.
3. The method of claim 1 or 2 , wherein the Top1-directed chemotherapeutic compound is a camptothecin compound.
4. The method of claim 3 , wherein the camptothecin compound is selected from the group consisting of lactocamptothecin, topotecan, irinotecan, SN-38, rubitecan, gimatecan, karenitecin, silatecan, exatecan, lurtotecan and diflomotecan.
5. The method of claim 1 or 2 , wherein the cancer is selected from the group consisting of: colorectal cancer, breast cancer, lung cancer, adenosquamous lung carcinoma, B-Cell acute lymphoblastic leukemia, bladder urothelial carcinoma, brain astrocytoma, breast adenocarcinoma, breast carcinoma, colon adenocarcinoma, colon carcinoma, ductal breast carcinoma, endometrial adenocarcinoma, endometrial endometrioid adenocarcinoma, esophageal squamous cell carcinoma, hepatocellular carcinoma, invasive ductal breast carcinoma, ovarian adenocarcinoma, rhabdomyosarcoma, squamous cell lung carcinoma, acute myeloid leukemia (AML), blast phase chronic myleogenous leukemia, brain glioblastoma, burkitts lymphoma, cutaneous melanoma, diffuse large B-cell lymphoma, gastric andenocarcinoma, gastric cancer, lung adenocarcinoma, melanoma, multiple myeloma, neuroblastoma, pancreatic adenocarcinoma, pancreatic ductal carcinoma, small cell lung carcinoma, T-cell acute lymphoblastic leukemia, and tongue squamous cell carcinoma.
6. The method of claim 1 or 2 , wherein the agent is an siRNA or shRNA.
7. The method of claim 1 , wherein the agent comprises SEQ ID NO: 6.
8. The method of claim 1 , wherein the agent comprises SEQ ID NO: 1.
9. The method of claim 1 , wherein the agent comprises SEQ ID NO. 2.
10. The method of claim 1 , wherein the agent comprises SEQ ID NO: 7.
11. The method of claim 2 , wherein the agent comprises SEQ ID NO: 6.
12. The method of claim 2 , wherein the agent comprises SEQ ID NO: 7.
13. The method of claim 2 , wherein the agent comprises SEQ ID NO: 1.
14. The method of claim 2 , wherein the agent comprises SEQ ID NO: 2.